Lees Pharmaceutical Holdings Valuation
| LPCUFDelisted Stock | USD 0.0001 0.00 0.00% |
Lees Pharmaceutical seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Lees Pharmaceutical from analyzing the firm fundamentals such as Profit Margin of (0.09) %, return on equity of -0.0531, and Current Valuation of 123.64 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Lees Pharmaceutical's price fluctuation is out of control at this time. Calculation of the real value of Lees Pharmaceutical is based on 3 months time horizon. Increasing Lees Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Lees pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Lees Pharmaceutical Holdings. Since Lees Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lees Pink Sheet. However, Lees Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real -0.002035 | Hype 1.25E-4 |
The real value of Lees Pink Sheet, also known as its intrinsic value, is the underlying worth of Lees Pharmaceutical Company, which is reflected in its stock price. It is based on Lees Pharmaceutical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Lees Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Lees Pharmaceutical Holdings helps investors to forecast how Lees pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lees Pharmaceutical more accurately as focusing exclusively on Lees Pharmaceutical's fundamentals will not take into account other important factors: Lees Pharmaceutical Total Value Analysis
Lees Pharmaceutical Holdings is now anticipated to have takeover price of 123.64 M with market capitalization of 275.66 B, debt of 84.09 M, and cash on hands of 368.05 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Lees Pharmaceutical fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
123.64 M | 275.66 B | 84.09 M | 368.05 M |
Lees Pharmaceutical Investor Information
About 64.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.0. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lees Pharmaceutical last dividend was issued on the 8th of September 2022. Lees Pharmaceutical Holdings is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Lees Pharmaceutical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lees Pharmaceutical has an asset utilization ratio of 34.81 percent. This implies that the Company is making $0.35 for each dollar of assets. An increasing asset utilization means that Lees Pharmaceutical Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Lees Pharmaceutical Ownership Allocation
Lees Pharmaceutical maintains a total of 588.84 Million outstanding shares. Lees Pharmaceutical Holdings secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 63.62 % of Lees Pharmaceutical Holdings outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lees Pharmaceutical Profitability Analysis
The company reported the revenue of 1.27 B. Net Income was 1.99 B with profit before overhead, payroll, taxes, and interest of 806.28 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Lees Pharmaceutical's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Lees Pharmaceutical and how it compares across the competition.
About Lees Pharmaceutical Valuation
The pink sheet valuation mechanism determines Lees Pharmaceutical's current worth on a weekly basis. Our valuation model uses a comparative analysis of Lees Pharmaceutical. We calculate exposure to Lees Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lees Pharmaceutical's related companies.Lees Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the Peoples Republic of China. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong. Lees Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1182 people.
8 Steps to conduct Lees Pharmaceutical's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Lees Pharmaceutical's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Lees Pharmaceutical's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Lees Pharmaceutical's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Lees Pharmaceutical's revenue streams: Identify Lees Pharmaceutical's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Lees Pharmaceutical's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Lees Pharmaceutical's growth potential: Evaluate Lees Pharmaceutical's management, business model, and growth potential.
- Determine Lees Pharmaceutical's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Lees Pharmaceutical's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Lees Pharmaceutical Growth Indicators
Investing in growth stocks can be very risky. If the company such as Lees Pharmaceutical does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 588.8 M | |
| Quarterly Earnings Growth Y O Y | 1.472 | |
| Retained Earnings | 3.5 B |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Lees Pink Sheet
If you are still planning to invest in Lees Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lees Pharmaceutical's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |